FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/23/2026

1. DHR
2. USO
3. NVDA
4. SPY
5. AMD
6. SMCI
7. NOW
8. GM
9. IBM
10. EFX

Go back to FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
BIOGEN IDEC Inc. (NASDAQ: BIIB) Delayed: 197.74 -5.42 (2.67%)
Previous Close $203.16    52 Week High $333.65 
Open $203.70    52 Week Low $223.02 
Day High $204.31    P/E 25.32 
Day Low $197.40    EPS $7.81 
Volume 841,352